Navidea Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Navidea Biopharmaceuticals has been growing earnings at an average annual rate of 49.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 99.5% per year.
Key information
49.3%
Earnings growth rate
71.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -99.5% |
| Return on equity | n/a |
| Net Margin | -1,444,993.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Navidea Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -9 | 5 | 5 |
| 30 Jun 23 | 0 | -14 | 5 | 5 |
| 31 Mar 23 | 0 | -16 | 5 | 6 |
| 31 Dec 22 | 0 | -17 | 5 | 6 |
| 30 Sep 22 | 0 | -17 | 6 | 5 |
| 30 Jun 22 | 0 | -12 | 7 | 5 |
| 31 Mar 22 | 0 | -12 | 7 | 5 |
| 31 Dec 21 | 1 | -12 | 7 | 5 |
| 30 Sep 21 | 1 | -11 | 7 | 5 |
| 30 Jun 21 | 1 | -12 | 7 | 5 |
| 31 Mar 21 | 1 | -12 | 7 | 5 |
| 31 Dec 20 | 1 | -11 | 7 | 5 |
| 30 Sep 20 | 1 | -11 | 6 | 5 |
| 30 Jun 20 | 1 | -11 | 6 | 6 |
| 31 Mar 20 | 1 | -11 | 6 | 6 |
| 31 Dec 19 | 1 | -11 | 6 | 5 |
| 30 Sep 19 | 1 | -11 | 5 | 4 |
| 30 Jun 19 | 1 | -12 | 7 | 4 |
| 31 Mar 19 | 1 | -12 | 7 | 4 |
| 31 Dec 18 | 1 | -16 | 7 | 4 |
| 30 Sep 18 | 1 | -19 | 10 | 5 |
| 30 Jun 18 | 1 | -17 | 9 | 5 |
| 31 Mar 18 | 2 | -18 | 9 | 5 |
| 31 Dec 17 | 2 | -14 | 11 | 5 |
| 30 Sep 17 | 2 | -10 | 9 | 5 |
| 30 Jun 17 | 4 | -10 | 10 | 5 |
| 31 Mar 17 | 5 | -8 | 8 | 6 |
| 31 Dec 16 | 5 | -7 | 8 | 7 |
| 30 Sep 16 | 8 | -9 | 10 | 8 |
| 30 Jun 16 | 10 | -15 | 12 | 11 |
| 31 Mar 16 | 12 | -24 | 14 | 11 |
| 31 Dec 15 | 3 | -23 | 11 | 11 |
| 30 Sep 15 | 11 | -32 | 17 | 12 |
| 30 Jun 15 | 9 | -31 | 16 | 12 |
| 31 Mar 15 | 8 | -31 | 17 | 15 |
| 31 Dec 14 | 2 | -30 | 10 | 15 |
| 30 Sep 14 | 5 | -43 | 15 | 24 |
| 30 Jun 14 | 3 | -47 | 17 | 26 |
| 31 Mar 14 | 2 | -47 | 16 | 25 |
| 31 Dec 13 | 1 | -43 | 16 | 24 |
Quality Earnings: NAVB is currently unprofitable.
Growing Profit Margin: NAVB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NAVB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NAVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NAVB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NAVB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.